Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$718.00K$718.00K−66.0% vs Q2 2016 Net Income-$7.31M-$7.31MN/M vs Q2 2016 EPS Diluted-$0.34-$0.34N/M vs Q2 2016 Operating Income-$7,350,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,183,000N/M Margins · derivedOperating margin-1023.7%−905.9 pt vs Q2 2016
Net margin-1018.4%−899.5 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 11, 2017 · 42 d after period end